Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
From October 1990 to September 1991, 20 consecutive patients with histologically proven malignant pleural mesothelioma (MPM), secondary to environmental exposure to asbestos or erionite, were treated with cisplatin, mitomycin C and alpha interferon (cisplatin 50 mg/m2 i.v. on day 1 of a 21-day cycle; mitomycin C 10 mg/m2 i.v. day 1 of cycles 1,3 and 5; alpha-2b-interferon 10 x 10(6) units i.m., 4 h prior to cisplatin and 10 x 10(6) units i.v. immediately prior to cisplatin day 1 of each cycle). Eighty-two treatment cycles were administered to 19 evaluable patients. Two patients attained a partial response. Eleven patients had stable disease and 6 had disease progression. Toxicities included interferon-related fever and flu-like symptoms, and vomiting. Actuarial median survival was 15 months. Three patients are alive at 20+, 21+ and 27+ months. We conclude that while the addition of alpha interferon to cisplatin and mitomycin C did not result in an objective response higher than previously reported with the cytotoxic agents alone, the trend towards an improvement in median survival as compared to a well-matched historical group suggests some benefit from the inclusion of interferon.
Tansan
S
S
Section of Medical Oncology, Evans Memorial Department of Clinical Research, Boston University Medical Center, Mass.
Emri
S
S
Selçuk
T
T
Koç
Y
Y
Hesketh
P
P
Heeren
T
T
McCaffrey
R P
RP
Bariş
Y I
YI
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001194:Asbestos / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004781:Environmental Exposure / Q000009:adverse effects; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008654:Mesothelioma / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010997:Pleural Neoplasms / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
D016898:Interferon-alpha; D001194:Asbestos; D016685:Mitomycin; D002945:Cisplatin